Abstract
For the systemic application of nucleic acids such as plasmid DNA and small interfering RNA, safe and efficient carriers that overcome the poor pharmacokinetic properties of nucleic acids are required. A cationic liposome that can formulate lipoplexes with nucleic acids has significant promise as an efficient delivery system in gene therapy. To achieve in vivo stability and long circulation, most lipoplexes are modified with PEG (PEGylation). However, we reported that PEGylated liposomes lose their long-circulating properties when they are injected repeatedly at certain intervals in the same animal. This unexpected and undesirable phenomenon is referred to as the accelerated blood clearance (ABC) phenomenon. Anti-PEG IgM produced in response to the first dose of PEGylated liposomes has proven to be a major cause of the ABC phenomenon. Therefore, in a repeated dosing schedule, the detection of anti-PEG IgM in an animal treated with PEGylated lipoplex could be essential to predict the occurrence of the ABC phenomenon. This chapter introduces a method for the evaluation of serum anti-PEG IgM by a simple ELISA procedure, and describes some precautions associated with this method.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Klibanov AL, Maruyama K, Torchilin VP, Huang L (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268:235–237
Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133–141
Lasic DD (1996) Doxorubicin in sterically stabilized liposomes. Nature 380:561–562
Maeda H, Bharate GY, Daruwalla J (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409–419
Judge A, McClintock K, Phelps JR, Maclachlan I (2006) Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 13:328–337
Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC (2000) Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292:1071–1079
Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ, van Rooijen N, Corstens FH, Storm G (2001) Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 298:607–612
Ishida T, Maeda R, Ichihara M, Irimura K, Kiwada H (2003) Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release 88:35–42
Ishida T, Masuda K, Ichikawa T, Ichihara M, Irimura K, Kiwada H (2003) Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm 255:167–174
Ishida T, Ichihara M, Wang X, Kiwada H (2006) Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release 115:243–250
Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E, Kiwada H (2006) Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 112:15–25
Wang X, Ishida T, Kiwada H (2007) Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release 119:236–244
Tagami T, Nakamura K, Shimizu T, Yamazaki N, Ishida T, Kiwada H (2010) CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. J Control Release 142:160–166
Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H (2007) PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 122:349–355
Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H (2009) Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Control Release 137:234–240
Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H (2011) Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Control Release 151:149–154
Allen TM, Sapra P, Moase E (2002) Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett 7:889–894
Ichihara M, Shimizu T, Imoto A, Hashiguchi Y, Uehara Y, Ishida T, KIwada H (2011) Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics 3:1–11
Acknowledgments
The authors thank Dr. James L. McDonald for his helpful advice in developing the English manuscript. This research was supported by a Grant-in-Aid for Young Scientists (A) (21689002) and a Grant-in-Aid for Scientific Research (B) (23390012) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Ichihara, M., Moriyoshi, N., Lila, A.S.A., Ishida, T., Kiwada, H. (2013). Anti-PEG IgM Production via a PEGylated Nano-Carrier System for Nucleic Acid Delivery. In: Ogris, M., Oupicky, D. (eds) Nanotechnology for Nucleic Acid Delivery. Methods in Molecular Biology, vol 948. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-140-0_4
Download citation
DOI: https://doi.org/10.1007/978-1-62703-140-0_4
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-139-4
Online ISBN: 978-1-62703-140-0
eBook Packages: Springer Protocols